Skyhawk to receive $54M up front & is also eligible to receive ~$2B in milestones along with royalties on future sales
Sanofi gets an exclusive option to license global intellectual property rights for candidates directed to program targets that emerges from the collaboration & will be responsible for further development and commercialization
The companies will use Skyhawk’s SkySTAR platform to discover and develop novel small molecules that modulate RNA splicing for oncology and immunology targets. SkySTAR platform combines computational biology techniques, kinetic models, and conformational structural models of RNA that help to develop therapies for disease targets that now have few or no therapeutic alternatives
Ref: PRNewswire | Image: Sanofi
